Exploratory Single-arm, Single-center Adjuvant Treatment of Stage IIIB-IIIC Gastric Cancer With Combination of Palizumab and SOX Regimen

An Exploratory Single-Arm, Single-Center Study of Pembrolizumab in Combination With SOX Regimen for Adjuvant Treatment of Stage IIIB-IIIC Gastric Cancer

it is an an Exploratory Single-Arm, Single-Center Study of Pembrolizumab in Combination with SOX Regimen for Adjuvant Treatment of Stage IIIB-IIIC Gastric Cancer

Inclusion Criteria:

• 1. Subjects voluntarily join the study and sign an informed consent form; 2. Male or female patients between the ages of 18-75; 3. Adenocarcinoma of the gastric/esophagogastric junction after radical resection was staged at stage IIIB-IIIC; 4. The molecular pathology of gastric cancer must meet at least one of the following three conditions:

  1. Consistent with high-frequency microsatellite instability MSI-H
  2. Consistent with high tumor mutation load TMB-H (≥10 mutations/megabases)
  3. High expression of PD-L1 (CPS score ≥5) 5. Expected survival time > 6 months； 6. ECOG (Eastern US Cooperative Oncology Group) score: 0-1 points; 7. Have not received anti-tumor immunotherapy; 8. Agree to provide archived tumor tissue samples for molecular testing; 9. Have good organ function:

  1. Hemoglobin ≥90g/L;

  2. Absolute neutrophil count ≥1.5×109/ L;

  3. Platelet count ≥100×109/ L;

  4. aspartate or alanine aminotransferase ≤ 2.5 times the upper limit;

  5. alkaline phosphatase ≤ 2.5 times the upper normal limit ; 10. Women of reproductive age who need to use a medically approved contraceptive method (such as an IUD, contraceptive pill, or condom) during the study treatment period and for 3 months after the end of the study treatment period; For men who agreed to use an appropriate method of contraception during the trial and for 3 months after the last dose of the trial drug.

     11. Women of reproductive age must be negative for serum or urine HCG within 72 hours prior to study entry. And must be non-lactating.

     Exclusion Criteria:

  1. Patients with severe hypertension and poor drug control;
  2. Patients with difficulty in taking oral drugs due to dysphagia, complete or incomplete digestive tract obstruction, active gastrointestinal bleeding, perforation, etc.;
  3. People who are known to be allergic to the ingredients in the test drug or have metabolic disorders;
  4. Simultaneously participating in other tumor experimental drugs or being in other tumor clinical trials.
  5. Severe liver disease (such as cirrhosis, etc.), kidney disease, respiratory disease or uncontrollable diabetes, hypertension and other chronic system diseases; Clinically obvious heart disease, such as congestive heart failure, obvious coronary heart disease, medically difficult to control arrhythmia, hypertension, or myocardial infarction within 6 months, or cardiac insufficiency;
  6. Patients with peripheral nervous system disorders or a history of obvious mental disorders and central nervous system disorders;
  7. Diagnosed with immunodeficiency or received systemic hormone therapy or other forms of immunosuppressive therapy within 7 days prior to initial administration;
  8. Active period > CTCAE (Version 5.0) grade 2 clinical severe infection;
  9. Pregnant and lactating women, women of childbearing age and their spouses refuse to take effective contraceptive methods;
  10. Persons without legal capacity, whose medical or ethical reasons affect the continuation of the research.
  11. Other conditions determined by the investigator to be unsuitable for inclusion in the study.